Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer.367, 1783–1791 (2012). Clin. Cancer Res. Bachelot, T. et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group...
The article discusses research being done on the cost effectiveness of trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. It references several studies published in the February 2007 issue of the "Journal of Clinical Oncology." The first study ...
Trastuzumab deruxtecan is an antibody–drug conjugate with high extracranial activity in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. We conducted the prospective, open-label, single-arm, phase 2 TUXEDO-1 trial. We enrolled patients aged ≥18 years with HER2...
(5) Life expectancy was more than 6 months. Exclusion criteria are as follows: (1) received any treatment for breast cancer before. (2) Inflammatory breast cancer (IBC), occult breast cancer, bilateral breast cancer, or distant metastasis. Abdominal and pelvic ultrasonography, chest CT, and ...
The dual primary end points of overall survival and progression-free survival were encouraging when patients with hormone receptor-positive, HER2-negative breast cancer were treated with datopotamab deruxtecan.
inoperable or metastatic HR-positive, HER2-negative breast cancer, progressed on or are not eligible for endocrine therapy, have an ECOG performance status of 0 or 1, at least 1 measurable lesion, adequate organ and bone marrow function, and a minimum life expectancy of 12 wee...
Currently approved HER2-targeting antibody-drug conjugates (ADCs) for HER2-positive breast cancer (BC) are associated with safety concerns. In this multicenter, single-arm, dose-escalation (phase 1a) and dose-expansion (phase 1b) phase 1 trial (NCT039444
Patients with brain metastases of HER2-positive breast cancer (BC) is a special group of patients who are difficult to treat and have a short life expectancy. The possibilities of whole brain radiotherapy, stereotactic radiosurgery and surgery in such patients are rather limited. Trastuzumab emtansine...
The efficacy of the antibody drug conjugate (ADC) Trastuzumab deruxtecan (T-DXd) in HER2 low breast cancer patients suggests that the historical/conventional assays for HER2 may need revision for optimal patient care. Specifically, the conventional assay
"Since we discovered HER2 inhibitors,life expectancyfor patients with HER2-positive breast cancer has improved tremendously, because we're able to block one of the main drivers of this cancer," Shagisultanova says. "If we just use chemotherapy and don't block HER2,cancer cellsdivide faster than...